To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer

Официальное название

A Phase I Clinical Study to Explore the Safety and Efficacy of Hypervision Proton Surgery (HyPROS) for Early-stage Non-small Cell Lung Cancer

Обзор

This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.

Подробное описание

This study adopted a dose escalation protocol (an improved "two-stage two-dose group" design) to explore the safety and efficacy of visual proton surgery (single large fractionated doses of 34GyE and 39GyE) in the treatment of early peripheral NSCLC.

Вмешательства

• Лучевая терапия Hypervision proton surgery
  Proton radiaotherapy (34GyE or 39GyE)

Первичные конечные точки

• The incidence of grade ≥ 3 psAEs at 1 month [Срок оценки: 1 month after proton radiotherapy]
• The incidence of grade ≥ 3 psAEs at 1 year [Срок оценки: 1 year after proton radiotherapy]

Вторичные конечные точки (3)

• Primary tumor control at 1 year [Срок оценки: 1 year after proton radiotherapy]
• Disease-free survival time [Срок оценки: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]
• Overall survival time [Срок оценки: From date of treatment until the date of death]

Критерии участия

Критерии включения

• The patient must be at least 18 years old
• Karnofsky Performance Status > 80
• NSCLC confirmed by cytology or histology; for subjects who cannot safely obtain pathological evidence due to factors such as tumor lesion location, patient's underlying diseases, or high puncture risk, after unanimous consent of the multidisciplinary team (MDT) discussion, they meet the clinical diagnostic criteria for NSCLC based on typical imaging features (such as enhanced chest CT and/or PET/CT) combined with clinical manifestations;
• Early-stage tumors are defined as T1 (≤3cm) N0M0 based on enhanced computed tomography (CT) and positron emission tomography (PET)
• The tumor must be more than 2 cm away from the proximal bronchial tree in all directions (the proximal bronchial tree is defined as 2 cm from the distal end of the trachea, the protrusion and the named lobar bronchus up to its first bifurcation)
• FEV1 ≥ 1 L, FEV1 ≥ 40% of the predicted value (either one is sufficient); DLCO ≥ 40% of the predicted value
• The patient can tolerate PET-CT examination
• For female study participants of childbearing age, the urine or serum pregnancy test was negative within 7 days prior to the first administration of the study drug. If the result of the urine pregnancy test is positive, a blood pregnancy test is required

Критерии исключения

• Other malignant tumors occurred concurrently within 2 years before enrollment
• A history of chest radiotherapy in the past
• It is planned to use other anti-tumor treatments within the regimen treatment (within 4 weeks)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Anhui Provincial Hospital — Хэфэй

Идентификаторы

NCT: NCT07195084 · HyPROS

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗